

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1390 (Modified) (REV 11-2000)			
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		VN29	
INTERNATIONAL APPLICATION NO PCT/GB00/03507	INTERNATIONAL FILING DATE 12 September 2000 (12.09.00)	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 10 / 070005	
		PRIORITY DATE CLAIMED 27 September 1999 (27.09.99)	
TITLE OF INVENTION SCAR TREATMENT COMPOSITION			
APPLICANT(S) FOR DO/EO/US Gary LORD; Marie Therese VALENCIA; Xavier THOMAS			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 			
Items 13 to 20 below concern document(s) or information included: <ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 23. <input checked="" type="checkbox"/> Other items or information: 			
Return Post Card			

U.S. APPLICATION NO (IF KNOWN, SEE 37 CFR 10/070005	INTERNATIONAL APPLICATION NO. PCT/GB00/03507	ATTORNEY'S DOCKET NUMBER VN29
24. The following fees are submitted:.		CALCULATIONS PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5) : <ul style="list-style-type: none"> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$890.00
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).		<input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 \$130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total claims	14 - 20 =	0
Independent claims	2 - 3 =	0
Multiple Dependent Claims (check if applicable).		<input type="checkbox"/> \$0.00
TOTAL OF ABOVE CALCULATIONS =		\$1,020.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.		\$0.00
SUBTOTAL =		\$1,020.00
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).		<input type="checkbox"/> 20 <input type="checkbox"/> 30 + \$0.00
TOTAL NATIONAL FEE =		\$1,020.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).		<input type="checkbox"/> \$0.00
TOTAL FEES ENCLOSED =		\$1,020.00
		Amount to be: refunded \$
		charged \$
<p>a. <input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 04-1520 in the amount of \$1,020.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1520 A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>		
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>		
SEND ALL CORRESPONDENCE TO:		
<p>Roger E. Gobrogue DOW CORNING CORPORATION Mail Station C01232 2200 West Salzburg Road P.O. Box 994 Midland, Michigan 48686-0994</p>		
 Roger E. Gobrogue NAME 33,616 REGISTRATION NUMBER February 27, 2002 DATE		

SCAR TREATMENT COMPOSITION

The present invention relates to a novel composition comprising a silicone fluid, a silicone gum, a silicone wax and a volatile silicone. This composition can be used for 5 the treatment of scars resulting from injury or surgery.

Scars resulting from injury or surgery are undesirable both cosmetically and functionally. Cosmetically, scar tissue is often viewed as unsightly. Functionally, scar 10 tissue often lacks features of undamaged skin such as a normal sense of touch and complete skin integrity.

Numerous methods have been developed to treat and/or prevent scars including surgical treatment, aftercare coverings, pressure treatment, oils, creams, greases, wound 15 dressings such as hydrogel or silicone gels, collagen implantation and laser ablation. For instance, United States Patent Number 4,991,574 teaches a surgical dressing comprising a sheet of silicone gel having a wound-facing surface and, laminated to the other surface, a film of 20 silicone elastomer. This dressing, however, is cumbersome for patients to apply and is difficult to adhere and maintain adherence on certain parts of the body.

Likewise, United States Patent Number 5,741,509 teaches a wound dressing comprising a blend of silicone fluid, fumed 25 silica and a volatile diluent. This patent teaches that the volatile diluent reduces the consistency of the composition so that it can be applied to a wound without producing injury or discomfort. When the volatile diluent evaporates, a stiff cream having increased wound adhesion is left. This 30 material, however, is tacky and fails to provide sufficient occlusivity.

Therefore, one of the objects of the present invention is to provide a scar treatment composition that forms films

-2-

on the skin which are substantive, semi-occlusive, non-tacky, cosmetically acceptable and easy to apply and remove.

We have now discovered that these properties are delivered by a composition comprising 1-25 wt. % of a 5 silicone gum, 1-40 wt. % of a silicone fluid having a viscosity of 10 to 60,000 mm²/s, 1-35 wt. % of a silicone wax and 20-90 wt. % of a volatile silicone fluid having a viscosity up to and including 5 mm²/s.

These compositions can be used for the treatment of 10 scars resulting from injury or surgery.

The compositions of the present invention have numerous properties which render them useful for forming films on the skin. These include, for example, the films are substantive such that they do not smear, transfer to clothing or exhibit 15 cold flow. Similarly, the films are semi-occlusive such that they provide an emollient and moisturizing effect.

Additionally, the compositions are aesthetically pleasant in that they are not tacky (i.e., they have a silky feel), they have a matte appearance (i.e., not shiny), they are 20 comfortable when applied, and they are easy to apply and remove.

Of particular significance is the fact that the compositions of the present invention can be produced in any form from a liquid to a thick paste and, thus, can be 25 delivered by any conventional means.

The first ingredient of the compositions of the invention are silicone gums. These gums provide the compositions herein with the ability to form substantive, matte films and, conversely, without such gums the 30 compositions of the invention are sticky and easily removed (e.g., washing or smearing). While such gums are typically high molecular weight polydimethylsiloxanes terminated with unreactive groups such as trimethylsiloxy or reactive groups such as dimethylhydroxysiloxy or dimethylvinylsiloxy,

-3-

nearly any silicone gum, or mixtures thereof, will function herein. Most preferably, the silicone gum is a dimethylhydroxysiloxy -terminated polydimethylsiloxane.

5 Silicone gums typically have viscosities up to 50 million mm²/s at 25⁰C and have number average molecular weights (Mn) of up to 700,000 or more. Preferably, the gums have an Mn of about 200,000 to 400,000.

10 Such gums and methods for their production are known in the art as exemplified by Noll, Chemistry and Technology of Silicones, Academic Press, 1968. In addition, silicone gums are commercially available from, for example, Dow Corning Corporation.

Generally, silicone gums are added to the composition of the invention in amounts of about 1 to 25 wt %.

15 Preferably, silicone gums are used in an amount of about 5 to 15 wt %.

20 The composition of the invention also contains silicone fluids having viscosities of about 10 to 60,000 mm²/s at 25⁰C. These fluids plasticize the compositions herein and improve their spreadability and conformability. While such fluids are typically linear polydimethylsiloxanes terminated with unreactive groups such as trimethylsiloxy or reactive groups such as dimethylhydroxysiloxy or dimethylvinylsiloxy, nearly any silicone fluid, or mixtures thereof, will

25 function herein. This includes, for example, fluids with small amounts of branching or fluids with organic groups other than methyl attached to silicon.

30 As noted, the silicone fluids herein will have viscosities of about 10 to 60,000 mm²/s at 25⁰C. Preferably, the silicone fluids will have viscosities of about 20 to 20,000 mm²/s at 25⁰C. Most preferably, the silicone fluid comprises a mixture of silicone fluids having viscosities of about 20 and about 12,500 mm²/s at 25⁰C.

-4-

Such fluids and methods for their production are known in the art as exemplified by Noll, Chemistry and Technology of Silicones, Academic Press, 1968. In addition, silicone fluids are commercially available from, for example, Dow 5 Corning Corporation.

Generally, silicone fluids are added to the composition of the invention in amounts of about 1 to 40 wt %.

Preferably, silicone fluids are used in an amount of about 20 to 30 wt %.

10 The composition of the invention also contains silicone waxes. These waxes provide the compositions herein with their silky, non-tacky and semi-occlusive properties. The occlusive property, in turn, provides skin hydration which is a major factor in scar treatment. These waxes also act as 15 a hardening lubricant which causes a reduction in the elastic contribution of the gums under stress and a reduction in the creep of the film. Nearly any silicone wax, or mixtures thereof, will function herein.

Preferred silicone waxes suitable for use in the 20 present invention include alkylmethysiloxane copolymers having the following formulations:

1. $(RMeSiO)_a(Me_2SiO)_b$

or

2. $R'Me_2(RMeSiO)_y(Me_2SiO)_zSiMe_2R'$

25 wherein R is C_nH_{2n+1} , R' is R or Me, Me is CH_3 , n is 5 to 45, preferably 10-30, a is an integer from 3 to 10, b is an integer of 0 to 10, a + b is 3 to 10 and y and z are independently 0 or a positive integer of, for example, 1-1000, provided the resultant material is waxy in character, 30 i.e., when R' is Me, y must be 1 or greater.

Preferably, the silicone wax comprises a trimethylsiloxy-terminated poly(dimethyl, methyloctadecyl)siloxane.

-5-

The silicone waxes of the present invention typically have melting points of between about 30° C and about 100° C.

Methods for the preparation of such materials are known in the art, and such methods are described in, for example, 5 U.S. Pat. No. 5,017,221 which issued May 21, 1991, and U.S. Pat. No. 5,160,494 which issued Nov. 3, 1992, both of which are incorporated herein by reference. Basically, such methods involve the reaction of a linear siloxane having SiH functionality in the chain with a cyclic siloxane containing 10 Me_2SiO units, and contacting the reaction product with a slight stoichiometric excess of an alkene in the presence of a platinum on carbon catalyst. In addition, silicone waxes are commercially available from, for example, Dow Corning Corporation.

15 Generally, silicone waxes are added to the composition of the invention in amounts of about 1 to 35 wt %. Preferably, silicone waxes are used in an amount of about 5 to 15 wt %.

20 The compositions of the invention also contain volatile silicone fluids having viscosities of up to and including about 5 mm^2/s . This volatile fluid allows for easy blending and application of the composition to form a thin film without a cold flow effect. While such fluids are typically cyclic or linear polydimethylsiloxanes or permethylsilanes, 25 nearly any volatile silicone fluid, silane, or mixtures thereof, will function herein.

As noted, the volatile silicone fluids generally have a 30 viscosity of up to and including about 5 mm^2/s , preferably up to about 1.5 mm^2/s at 25° C and more preferably up to about 1.0 mm^2/s at 25° C such that they volatilize in the ambient environment. Generally, such volatile silicone fluids correspond to the average unit formula $(\text{CH}_3)_a\text{SiO}(4-a)/2$ where a has an average value of from 2 to 3. Such

-6-

fluids often comprise siloxane units joined by Si-O-Si bonds selected from the group consisting of $(CH_3)_3SiO_{1/2}$ and $(CH_3)_2SiO_{2/2}$ units taken in such molar amounts so that there is an average of from approximately two to three methyl groups per silicon in the fluid.

The volatile silicone fluids of the invention can also be a permethylsilane corresponding to the average unit formula $(CH_3)_aSi$ where a has an average value of from 2 to 3. Such fluids comprises silane units joined by Si-Si bonds selected from the group consisting of $(CH_3)_3Si$ and $(CH_3)_2Si$ units taken in such molar amounts so that there is an average of from approximately two to three methyl groups per silicon in the fluid.

Preferably the silicone fluid consists essentially of dimethylsiloxane units, and optionally, trimethylsiloxane units. Of particular interest in the present invention are methylsiloxane fluids such as the cyclopolsiloxanes of the general formula $\{(CH_3)_2SiO\}_x$ and linear siloxanes of the general formula $(CH_3)_3SiO\{(CH_3)_2SiO\}_ySi(CH_3)_3$ wherein x is an integer of from 4 to 6 and y is an integer of from 0 to 4.

Preferred silicone fluids or blends of silicone fluids include cyclic silicones such as hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and the like and linear silicones such as hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane, and the like. The preferred volatile silicone fluid is hexamethyldisiloxane.

These volatile silicone fluids and methods for their manufacture are known in the art as exemplified by Noll, Chemistry and Technology of Silicones, Academic Press, 1968. In addition, these volatile silicone fluids are commercially available from, for example, Dow Corning Corporation.

-7-

Generally, the volatile silicone fluids are added to the composition of the invention in amounts of about 1 to 90 wt %, preferably 20 to 90 wt % and more preferably 40 to 70 wt %.

5 The compositions of the present invention may be prepared by simply mixing the components in any desired order. Apparatuses such as stirrers, blenders, mills and the like, and any other means known in the art can be used. In addition pressure vessels, condensing systems and other
10 means known in the art and commonly used to retain a volatile component in a mixture may be employed in the preparation of the present invention.

By changing the ratio of components in the compositions of the present invention, one has great flexibility in
15 producing compositions with a wide range of physical properties and, thus, a wide range of utilities. For example, compositions from liquids to pastes can be produced and these compositions can be changed to suit the type of scar. Similarly, the compositions may be changed for uses
20 outside scar treatment such as in cosmetics, skin care, pharmaceutical delivery, veterinary applications and the like.

The composition of the invention can optionally comprise other ingredients such as additional diluents,
25 dispersants or carriers, emollients, humectants, thickeners, fillers, preservatives, stabilizers, buffer systems, plant extracts, amino acids, activity enhancers, cosmetic ingredients such as colorants, perfumes, emulsifiers, and sunscreens, essential oils, antiparasitics, repellents and
30 pharmaceutical agents.

The following non-limiting examples are provided so that one skilled in the art can more readily understand the invention.

Example 1

The present example shows the moisture vapor transmission rate for compositions of the present invention and comparative materials.

5 Composition A was prepared by thoroughly mixing 26.38 g of dimethylhydroxysiloxy-terminated polydimethylsiloxane gum having an Mn of about 300,000; 18.67 g of trimethylsiloxy-terminated polydimethylsiloxane fluid having a viscosity of 12,500 mm²/s; 37.04 g of trimethylsiloxy-terminated polydimethylsiloxane fluid having a viscosity of 20 mm²/s and 17.9 g of trimethylsiloxy-terminated poly(dimethyl, methyloctadecyl)siloxane wax having a melting point of 32°C. 43 g of composition A was dispersed into 57 g of hexamethyldisiloxane.

15 Composition B was prepared by thoroughly mixing 26.2 g of dimethylhydroxysiloxy-terminated polydimethylsiloxane gum having an Mn of about 300,000; 19.2 g of trimethylsiloxy-terminated polydimethylsiloxane fluid having a viscosity of 12,500 mm²/s; 36.8 g of trimethylsiloxy-terminated polydimethylsiloxane fluid having a viscosity of 20 mm²/s and 17.8 g of trimethylsiloxy-terminated poly(dimethyl, methyloctadecyl)siloxane wax having a melting point of 32°C. 43 g of composition B was dispersed into 57 g of hexamethyldisiloxane.

25 A comparative composition C was prepared by thoroughly mixing 26.2 g of dimethylhydroxysiloxy-terminated polydimethylsiloxane gum having an Mn of about 300,000; 19.2 g of trimethylsiloxy-terminated polydimethylsiloxane fluid having a viscosity of 12,500 mm²/s and 36.8 g of trimethylsiloxy-terminated polydimethylsiloxane fluid having a viscosity of 20 mm²/s. 43 g of composition C was dispersed into 57 g of hexamethyldisiloxane.

-9-

A second comparative composition D comprising lot 1128/107 of the commercial gel Kelocote™ from Allied Biomedical, Paso Robles, CA. .

Each of these materials, compositions A, B, C and D, 5 were tested for moisture vapor transmission rate. The experiment was based on the ASTM E96-95 entitled "Standard Test Methods for Water Transmission of Materials" and conducted according to the following parameters : 1) About 14.5 mg/cm² of tested material was coated with a handcoater 10 onto a 55 mm diameter disc made from a microporous membrane which supports the material during the test. The microporous membrane is a PET membrane with an average pore size of 0.2 µm from 3M™ referenced as 3M™ CoTran 9711 Membrane. 2) Each 15 coated disc was put onto a cylindrical cup (h # 40 mm, Ø # 40 mm) which contains 20 ml of demineralised water. 3) The trials were done in a climatic system at a temperature of 32°C and at 50% relative humidity. The results are shown in Table 1.

20 Table 1 :

Composition	Coated weight (mg/cm ²)	MVTR (g/m ² .24h)
A	14.9	112.4
B	14.1	109.4
C	13.5	183.5
D	15.9	175.5
blank (membrane CoTran)	0	2625.7

MVTR = Moisture Vapor Transmission Rate

-10-

Example 2

The present example shows the oxygen permeability for materials of the present invention and comparative materials.

5 Composition A and comparative compositions C and D were prepared as in Example 1.

Each of these materials was tested for oxygen permeability. The experiment was based on a chromatographic method as documented in the ISO/CD 15105-2 and conducted 10 according to the following parameters : 1) About 17.2 mg/cm² of tested material was coated with a handcoater onto a 55 mm diameter disc made from a microporous membrane which supports the material during the test. The microporous membrane is a PET membrane with an average pore size of 0.2 15 µm from 3M™ referenced as 3M™ CoTran 9711 Membrane. 2) Each coated disc was put into the chromatography cell to form a 0.5 cm² interface between a flow of helium as chromatographic carrier gas and a flow of gas at atmospheric pressure containing 50% oxygen. 3) The trials were done at a 20 temperature of 23°C and at 0% relative humidity. The results are shown in Table 2.

Table 2 :

Composition	Coated weight (mg/cm ²)	Oxygen gas permeability (cm ³ /m ² .24h.bar)
A	15.4	52,000
C	19.5	201,600
D	16.8	201,600
blank (membrane CoTran) based on standard NF Q 03076	0	around 10 ¹⁰

-11-

Example 3

The present example shows the rheological behaviour for materials of the present invention and comparative materials.

5 Composition A was made by the process described in Example 1.

Comparative composition E was prepared by thoroughly mixing 262.1 g of dimethylhydroxysiloxy-terminated polydimethylsiloxane gum having an Mn of about 300,000; 192
10 g of trimethylsiloxy-terminated polydimethylsiloxane fluid having a viscosity of 12,500 mm²/s and 368 g of trimethylsiloxy-terminated polydimethylsiloxane fluid having a viscosity of 20 mm²/s. 43 g of composition E was dispersed into 57 g of hexamethyldisiloxane. A second comparative
15 composition F comprises only dimethylhydroxysiloxy-terminated polydimethylsiloxane gum having an Mn of about 300,000.

Each of these materials was tested for its rheological behaviour. The experiment was conducted by recording the
20 elastic and loss moduli of a 0.5 ml sample with a controlled stress rheometer (Carriimed™ CSL 500 from TA Instrument) equipped with a two-parallel plate geometry spaced from 100 µm and the upper plate has a 2 cm diameter. The test conditions were 1.75*10⁻² rad strain for 2 hours under 1 Hz
25 at 25°C. The results are shown in Table 3.

Table 3 :

Composition	G' (Pa)	G'' (Pa)
A	1,700	1,400
E	2,400	1,200
F	22,200	26,400

-12-

CLAIMS

1. A composition comprising:

1-25 wt. % of a silicone gum;

1-40 wt. % of a silicone fluid having a viscosity of 10 to 60,000 mm²/s at 25°C ;

1-35 wt. % of a silicone wax; and

20-90 wt. % of a volatile silicone fluid having a viscosity up to and including 5 mm²/s at 25°C.

2. The composition according to claim 1 wherein the silicone gum comprises a hydroxyl-terminated polydimethylsiloxane and is present in an amount of 5 to 15 wt %.

3. The composition according to claim 1 wherein the silicone fluid has a viscosity of 20 to 20,000 mm²/s at 25°C and is present in an amount of 20-30 wt %.

4. The composition according to claim 3 wherein the silicone fluid comprises a mixture of silicone fluids having a viscosity of about 20mm²/s at 25°C and 12,500 mm²/s at 25°C.

5. The composition according to claim 1 wherein the silicone wax comprises a trimethylsiloxy-terminated dimethyl, methyloctadecylsiloxane and is present in an amount of 5 to 15 wt %.

6. The composition according to claim 1 wherein the volatile silicone fluid comprises hexamethyldisiloxane and is present in an amount of 40 to 70 wt %.

-13-

7. The composition according to claim 1 also comprising a pharmaceutical agent.
8. The composition according to claim 1 also comprising a cosmetic ingredient.
9. The composition according to claim 1 also comprising a veterinary ingredient.
10. A method of forming a film on a substrate comprising:
(A) mixing components comprising:
1-25 wt. % of a silicone gum;
1-40 wt. % of a silicone fluid having a viscosity of 10 to 60,000 mm²/s at 25°C ;
1-35 wt. % of a silicone wax; and
20-90 wt. % of a volatile silicone fluid having a viscosity up to and including 5 mm²/s at 25°C;
(B) applying the mixture formed in (A) to a substrate; and
(C) allowing the volatile silicone fluid to evaporate and thereby deposit a film on the substrate.
11. The method of claim 10 wherein the substrate is skin.
12. The method of claim 10 wherein the mixture formed in (A) also comprises a pharmaceutical agent.
13. The method of claim 10 wherein the mixture formed in (A) also comprises a cosmetic ingredient.
14. The method of claim 10 wherein the mixture formed in (A) also comprises a veterinary ingredient.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/22923 A3

(51) International Patent Classification⁷: A61K 7/48, C08L 83/04, A61P 17/02

(74) Agents: VANDAMME, Luc, J. et al.; Dow Corning Limited, Cardiff Road, Barry CF63 2YL (GB).

(21) International Application Number: PCT/GB00/03507

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 12 September 2000 (12.09.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

— with international search report

(26) Publication Language: English

(88) Date of publication of the international search report: 7 September 2001

(30) Priority Data:

99402355.4 27 September 1999 (27.09.1999) EP

27 Sept 02

(71) Applicant (for all designated States except US): DOW CORNING FRANCE S.A. [FR/FR]; 20 boulevard E. Deruelle, F-69003 Lyon (FR).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): LORD, Gary [GB/FR]; Les Capucines, Chemin de la Ponchette, F-06330 Roquefort Les Pins (FR). VALENCIA, Marie-Thérèse [FR/FR]; 365 Chemin des Martelly, F-06580 Pegomas (FR). THOMAS, Xavier [FR/FR]; 7 bis avenue de Lerida, F-09000 Foix (FR).

WO 01/22923 A3

(54) Title: SCAR TREATMENT COMPOSITION

(57) Abstract: A composition comprising 1-25 wt.% of a silicone gum, 1-40 wt.% of a silicone fluid having a viscosity of 10 to 60,000 mm²/sec, 1-35 wt.% of a silicone wax and 20-90 wt.% of a volatile silicone fluid having a viscosity up to and including 5 mm²/s at 25 °C can be used for the treatment of scars resulting from injury or surgery.



Declaration and Power of Attorney for Patent Application
English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention titled:

SCAR TREATMENT COMPOSITION

the specification of which (check one):

is attached hereto.

was filed on **February 28, 2002** as United States Patent Application No. or PCT International Application Number **10/070,005** and was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Applications

Priority Not Claimed

99402355.4 (Number)	EP (Country)	27/September/1999 (Day/Month/Year Filed)	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>


I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)	(Filing Date)
(Application Serial No.)	(Filing Date)
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C.F.R. Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

PCT/GB00/03507 (Application Serial No.)	12/September/2000 (Filing Date)	Patented (Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Page 3 of 5
Docket No. VN29

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)


Jim L. DeCesare, Reg. No. 27,979
Catherine U. Brown, 44,565
Timothy J. Troy, Reg. No. 36,951
Larry A. Milco, Reg. No. 41,196

Roger E. Gobrogge, Reg. No. 33,616
Sharon K. Severance, Reg. No. 34,010
Patricia M. Scaduto, Reg. No. 39,827
Alan Zombeck, Reg. No. 45,260

SEND CORRESPONDENCE TO:

Dow Corning Corporation
Patent Department - C01232
P.O. Box 994
Midland, MI 48686-0994

DIRECT TELEPHONE CALLS TO: (name and telephone number)
Timothy J. Troy (989) 496-5533

Full name of sole or first inventor Gary Lord	Date
Sole or first inventor's signature 	29.05.2002
Residence Lasne, Belgium	
Citizenship British	
Post Office Address Rue de l'Ancienne Gare, 8, 1380 Lasne, Belgium.	

Full name of second inventor, if any Marie Therese Valencia	Date
Second inventor's signature	
Residence Pegomas, France	
Citizenship French	
Post Office Address 365 Chemin Des Martelly 06580 Pegomas, France	



POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Jim L. DeCesare, Reg. No. 27,979
Catherine U. Brown, 44,565
Timothy J. Troy, Reg. No. 36,951
Larry A. Milco, Reg. No. 41,196

Roger E. Gobrogge, Reg. No. 33,616
Sharon K. Severance, Reg. No. 34,010
Patricia M. Scaduto, Reg. No. 39,827
Alan Zombeck, Reg. No. 45,260

SEND CORRESPONDENCE TO:

Dow Corning Corporation
Patent Department - C01232
P.O. Box 994
Midland, MI 48686-0994

DIRECT TELEPHONE CALLS TO: (name and telephone number)
Timothy J. Troy (989) 496-5533

Full name of sole or first inventor Gary Lord	Date
Sole or first inventor's signature	
Residence Les Pins, France <i>FRX</i>	
Citizenship British	
Post Office Address Les Capucines, Chemin De La Ponchette 06330 Roquefort, Les Pins, France	


202

Full name of second inventor, if any Marie Therese Valencia	Date
Second inventor's signature <i>Patent</i>	<i>June 16, 2002</i>
Residence Pegomas, France <i>FRX</i>	
Citizenship French	
Post Office Address 365 Chemin Des Martelly 06580 Pegomas, France	

Full name of second inventor, if any

Xavier Thomas

Second inventor's signature




Date

29th May 2002

Residence

Foix, France



Citizenship


French

Post Office Address

7 Bis Avenue

De Lerida, 09000 Foix, France

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s) _____ of _____ Dra*ui*ngs _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

Scanned copy is best available.